Literature DB >> 21471992

HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa.

Nikoletta Nagy, Noor Almaani, Akio Tanaka, Joey E Lai-Cheong, Tanasit Techanukul, Jemima E Mellerio, John A McGrath.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21471992     DOI： 10.1038/jid.2011.85

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  16 in total

1.  Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.

Authors:  Vitali Alexeev; Julio Cesar Salas-Alanis; Francis Palisson; Lila Mukhtarzada; Giulio Fortuna; Jouni Uitto; Andrew South; Olga Igoucheva
Journal:  J Invest Dermatol       Date:  2017-07-20       Impact factor: 8.551

2.  Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.

Authors:  Su M Lwin; Farhatullah Syed; Wei-Li Di; Tendai Kadiyirire; Lu Liu; Alyson Guy; Anastasia Petrova; Alya Abdul-Wahab; Fiona Reid; Rachel Phillips; Maria Elstad; Christos Georgiadis; Sophia Aristodemou; Patricia A Lovell; James R McMillan; John Mee; Snaigune Miskinyte; Matthias Titeux; Linda Ozoemena; Rashida Pramanik; Sonia Serrano; Racheal Rowles; Clarisse Maurin; Elizabeth Orrin; Magdalena Martinez-Queipo; Ellie Rashidghamat; Christos Tziotzios; Alexandros Onoufriadis; Mei Chen; Lucas Chan; Farzin Farzaneh; Marcela Del Rio; Jakub Tolar; Johann W Bauer; Fernando Larcher; Michael N Antoniou; Alain Hovnanian; Adrian J Thrasher; Jemima E Mellerio; Waseem Qasim; John A McGrath
Journal:  JCI Insight       Date:  2019-06-06

Review 3.  Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa.

Authors:  Michael Vanden Oever; Kirk Twaroski; Mark J Osborn; John E Wagner; Jakub Tolar
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

Review 4.  Novel molecular therapies for heritable skin disorders.

Authors:  Jouni Uitto; Angela M Christiano; W H Irwin McLean; John A McGrath
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

Review 5.  Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.

Authors:  Ellie Rashidghamat; John A McGrath
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 6.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

Review 7.  Molecular therapeutics for heritable skin diseases.

Authors:  Jouni Uitto
Journal:  J Invest Dermatol       Date:  2012-11-15       Impact factor: 8.551

Review 8.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 9.  Dystrophic epidermolysis bullosa: a review.

Authors:  Satoru Shinkuma
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-26

Review 10.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.